SCHEDULE 13D/A: Hillhouse Funds Significantly Reduce BeiGene Stake, File Final Exit Amendment

HHLR Advisors and Hillhouse Investment Management have filed their final Schedule 13D amendment, disclosing a significant reduction in their beneficial ownership of BeiGene, Ltd. ordinary shares to 4.9% following a recent block trade.

Summary

• HHLR Advisors, Ltd. and Hillhouse Investment Management, Ltd. (collectively, "Reporting Persons") have filed Amendment No. 7 to their Schedule 13D, which serves as their final "exit filing" for BeiGene, Ltd.
• As of May 9, 2025, the Reporting Persons beneficially own an aggregate of 68,551,141 Ordinary Shares of BeiGene, Ltd.
• This aggregate ownership represents 4.9% of BeiGene's outstanding Ordinary Shares, calculated based on 1,403,311,086 shares outstanding as of May 2, 2025.
• The reduction in ownership is primarily due to HHLR Fund selling 16,000,000 Ordinary Shares on May 9, 2025.
• The sale was executed via a block trade with Goldman Sachs (Asia) Securities Limited at a price of HKD130 per Ordinary Share.
• The remaining beneficial ownership consists of 55,102,823 ordinary shares held by a fund managed by HHLR and 13,448,318 ordinary shares held by a fund managed by HIM (including 1,034,306 ADSs representing 13,445,978 ordinary shares).

Sentiment

Score: 4

Explanation: The sentiment is slightly negative because a major institutional investor is significantly reducing its stake and filing an 'exit' amendment, which can be interpreted by the market as a loss of confidence or a strategic divestment, potentially putting downward pressure on the stock price. However, it's not severely negative as it's a disclosure of a transaction rather than a negative operational announcement from the company itself.

Future Outlook

NA

Industry Context

This filing reflects a portfolio adjustment by a major institutional investor in the biotechnology and pharmaceutical sector. While specific to BeiGene, large block trades by significant shareholders can sometimes signal broader shifts in investor sentiment towards specific companies or sub-sectors within the industry, though this filing itself does not provide such commentary.

Stakeholder Impact

• Shareholders: The reduction in stake by a major institutional investor could lead to negative market sentiment and potential downward pressure on BeiGene's share price. Existing shareholders might see a decrease in the value of their holdings.
• Company Management: While not directly impacting operations, a significant divestment by a large investor might prompt management to consider investor relations strategies or address market concerns if the sale is perceived as a lack of confidence.

Key Dates

Keywords

BeiGene, HHLR Advisors, Hillhouse Investment Management, Schedule 13D, SEC filing, shareholding, block trade, institutional investor, equity stake, pharmaceuticals, biotechnology